Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) was featured in the “Bell2Bell Podcast,” a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Avricore Health’s CEO Hector Bremner joined the latest episode to discuss the company’s business model and its continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry. “We’re a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes,” Bremner said. “Our technology is a cloud-based solution that networks these high-quality analyzers from companies like Abbott and is able to then create a testing network in the pharmacy… The patient gets to keep their information, of course… but really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data that can be used for study and research purposes, which is a very, very high demand out there in the sector.”
To view the full press release, visit https://ibn.fm/kD8px
About Avricore Health Inc.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM) (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care solutions, announced a commercial agreement with…
NRx Pharmaceuticals (NASDAQ: NRXP) announced that the U.S. Food and Drug Administration cleared the company to…
Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular…
Oncotelic Therapeutics (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting…
VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy…
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free…